PD-L1 - Wikipedia
WEBPD-L1 also known as B7-H1 was characterized at the Mayo Clinic in 1999 as an immune regulatory molecule. [8] At that time, it was concluded that B7-H1 helps tumor cells evade anti-tumor immunity. [9]
B7-H1, a third member of the B7 family, co-stimulates T-cell
WEBHere, we describe a third member of the B7 family, called B7-H1 that does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator).
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
WEBJun 24, 2002 · Cancer cell–associated B7-H1 increases apoptosis of antigen-specific human T-cell clones in vitro, and the apoptotic effect of B7-H1 is mediated largely by one or more receptors other than PD-1.
PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: …
WEBMar 2, 2016 · Abstract. PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has elicited durable anti-tumor responses and long-term remissions in a subset of patients with a broad spectrum of cancers.
Programmed death ligand 1 signals in cancer cells - Nature
WEBJan 14, 2022 · Programmed death ligand 1 (PDL1; also known as CD274 and B7-H1) is an immune checkpoint molecule that was discovered to be expressed by heart, placenta, lung and skeletal muscle tissues and...
Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in …
WEBThe B7 homolog 1 (B7-H1)/programmed cell death 1 (PD-1) pathway has been demonstrated as a major mechanism of immune evasion in tumor site, and its blockade therapy shows very encouraging results in clinical trials.
Inducible expression of B7-H1 (PD-L1) and its selective role ... - PubMed
WEBThe B7 homolog 1 (B7-H1)/programmed cell death 1 (PD-1) pathway has been demonstrated as a major mechanism of immune evasion in tumor site, and its blockade therapy shows very encouraging results in clinical trials.
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
WEBApr 1, 2008 · B7-H1 is an immunoglobulin-like immune suppressive molecule broadly detectable on the majority of human and rodent cancers, and its functions have been attributed to delivering an inhibitory signal to its counter …
B7-H1 maintains the polyclonal T cell response by protecting ... - PubMed
WEBMar 20, 2018 · DCs can present multiple antigens (Ags) to stimulate dominant or subdominant T cell responses. Here, we show that immunization with multiple tumor Ag-loaded DCs, in the absence of B7-H1, vastly enhances cytotoxic T lymphocyte (CTL) responses to dominant Ag.
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy
WEBPD pathway blockade has elicited durable clinical responses in patients with a broad spectrum of cancers with a reasonable toxicity profile (Table 1). This therapy largely relies on efficient T cell infiltration into tumor and effector T cell function in the tumor microenvironment.
- Some results have been removed
Skip to content